AzTrials
AzTrials

Atherosclerosis Cardiovascular DiseasePhase 2NCT07422051

Erythrodiol in Pomace Olive Oil as a Protective Agent Against Atherosclerosis

A Phase 2 study testing Low erythrodiol dose, Medium erythrodiol dose and High erythrodiol dose in people with Atherosclerosis Cardiovascular Disease, run by Spanish National Research Council at 1 site in Spain.

Not yet recruiting

Opening soon. The study is approved but enrolment has not started yet. Sites may already take enquiries.

Sites and contacts
Official record
Search all trials

Trial summary

The goal of this postprandial clinical trial is to learn whether erythrodiol, a triterpene naturally present in pomace olive oil, can modulate the cell foam formation, ine of the first steps in atherosclerosis. Read more about this study

Who is it for?
Ages 18 to 40 yearsHealthy volunteers can take part
Conditions the study is for
Atherosclerosis Cardiovascular Disease
What is being tested?
Low erythrodiol dose, Medium erythrodiol dose and High erythrodiol dose
Could I receive a placebo?
No, everyone receives an active treatment
How many people
22 participants
Where
1 siteSpain
Study dates
21 Feb 2026to 30 Dec 2026
Phase
Phase 2
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 40 years
  • All sexes
  • Healthy volunteers accepted
  • Adult

Who may be able to join

  • Adults aged 18 to 40 years.
  • Male or female volunteers.
  • Healthy individuals with no diagnosed diseases.
  • Normal-weight participants with a Body Mass Index (BMI) between 18.5 and 24.9 kg/m².
  • Ability to provide voluntary informed consent.
  • Willingness to comply with all study procedures.
  • Availability to participate in the two-phase selection process, including initial screening and subsequent laboratory tests.

Who cannot join

  • Presence of any type of disease, including digestive, metabolic, endocrine, infectious, neoplastic conditions, or associated allergies and food intolerances.
  • Current use of any medication, except hormonal contraceptives.
  • Pregnant or breastfeeding women.
  • Participation in a clinical trial with an investigational product within the last 60 days, or current enrolment in a clinical trial.
  • Any physical or intellectual limitation that, in the opinion of the investigator, could impede following or completing the study protocol.

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

Javier Perona S. Perona, PhD contact

34954611550

perona@ig.csic.es

Spain1 site
  • Instituto de la Grasa-CSIC

    Seville, 41013

    Javier Perona S. Perona, PhD, +34954611550, perona@ig.csic.es

Other trials in Spain

About this study

The goal of this postprandial clinical trial is to learn whether erythrodiol, a triterpene naturally present in pomace olive oil, can modulate the cell foam formation, ine of the first steps in atherosclerosis. The main questions it aims to answer are:

Is erythrodiol bioavailable in humans when administered as pomace olive oil? Does acute erythrodiol intake reduce postprandial triglyceride excursions after a high-fat meal? Does erythrodiol reduce the intake of postprandial triglyceride-rich lipoproteins by macrophages?

Read more

Researchers will compare participants receiving test meals enriched with different concentrations of erythrodiol (low, medium, high) to see if the intervention leads to improved postprandial metabolic and vascular responses.

Participants will:

Attend the research facility after an overnight fast. Consume a high-fat test meal enriched with a different doses of erythrodiol

Undergo serial postprandial assessments over several hours, including:

Blood sampling for lipids, glucose, inflammatory markers, and oxidative stress biomarkers Monitoring of subjective tolerability and adverse events

Read the detailed description

The present project builds on previous studies in which we suggested that erythrodiol, a bioactive component of pomace olive oil, is capable of helping prevent cardiovascular diseases when administered as part of pomace oil, through the inhibition of atherosclerosis development.

A total of 22 adult volunteers, both women and men (18-40 years old), healthy and of normal weight, will be selected. Participants will be recruited in two phases.

In the first phase, recruitment will take place at Pablo de Olavide University. Inclusion criteria for this phase include: age between 18 and 40 years; body mass index (BMI) between 18.5 and 24.9 kg/m²; ability to provide informed voluntary consent; and willingness to comply with all study procedures. Candidates will be excluded if, at the time of recruitment, they exhibit any of the following: presence of any type of pathology (digestive, metabolic, endocrine, infectious, neoplastic, etc.) or food-related allergies or intolerances. Individuals taking any type of medication-except contraceptives-will also be excluded, as well as pregnant or breastfeeding women, and anyone who has participated in a clinical trial involving an investigational product within the past 60 days or is currently enrolled in a clinical trial. Furthermore, any person with a physical or intellectual limitation that, in the investigator's opinion, could prevent adherence to and completion of the protocol will be excluded. In this phase, only clinical history, age, weight, and height data will be collected.

In the second phase, only those subjects whose complete biochemical and hematological analyses produce results within normal ranges will be included in the study.

At the Virgen del Rocío Hospital (Seville), and after a 12-hour fast, three experiments will be conducted. In each of them, participants will be administered pomace olive oil containing different concentrations (low, medium, or high) of erythrodiol, the protective agent, in an amount of 50 g on each occasion. On the study day, blood samples will be taken (between 6 and 24 mL per draw and 90 mL total), 15 minutes before (baseline) and every hour for 6 hours after ingestion of a meal rich in the corresponding pomace oil. The meal will be accompanied by coffee (black, without sugar) or skimmed milk and whole-grain toast (3 slices). The consumption of these foods carries no health risk.

Venous access will be obtained by puncture with an Abbocath® catheter fitted with a Smartsite™ valve (Ivac®, Spec-Sets®) and a Vacutainer® system for sterile Hemogard® tubes with a silicone separator. This procedure involves only the risks inherent to simple blood sampling.

Part of the collected samples will be processed at the Clinical Analysis Laboratory Service of the Virgen del Rocío University Hospital for biochemical analysis, while another portion will be sent to the Instituto de la Grasa-CSIC.

In addition to these analyses, participants will undergo simple anthropometric measurements (weight, height, hip and waist circumference) as well as blood pressure assessment.

This procedure will be repeated after four weeks with a second oil, and four weeks later with the third one, so that all participants will have consumed all three oils.

Being tested
Low erythrodiol dose, Medium erythrodiol dose, High erythrodiol dose
Keywords
Randomized postprandial crossover trial, Erythrodiol, Pomace olive oil, Atherosclerosis, Macrophages
Medical subject headings
Atherosclerosis

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Low erythrodiol doseOther

    Low erythrodiol dose

  • Medium erythrodiol doseOther

    Medium erythrodiol dose

  • High erythrodiol doseOther

    High erythrodiol dose

Study groups in NCT07422051
Study groupRoleWhat they receive
Low erythrodiolActive comparatorNot described
Receives: Other: Low erythrodiol dose
Medium erythrodiolActive comparatorNot described
Receives: Other: Medium erythrodiol dose
High erythrodiolActive comparatorNot described
Receives: Other: High erythrodiol dose

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Plasma erythrodiol concentration

    Measured: 4 months since the last intervention session

Secondary outcomes (2)
  1. Plasma triglyceride concentration

    Measured: 4 months since the last intervention session

  2. Inflammation marker concentration in plasma

    Measured: 4 months since the last intervention session

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted19 Feb 2026
  2. Study start21 Feb 2026 (estimated)
  3. Primary completion30 Jun 2026 (estimated)
  4. Study completion30 Dec 2026 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 2
Primary purpose
Prevention
Allocation
Randomised
Intervention model
Crossover
Model description
This study uses a randomized, postprandial, crossover interventional design, in which each participant receives all three test conditions (low, medium, and high erythrodiol doses) in separate visits. Participants act as their own controls, and each intervention is separated by a washout period of 4 weeks to avoid carry-over effects.
Masking
Triple blind
Who is masked
Participant, Care provider, Investigator
Enrolment
22 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07422051
Sponsor's protocol ID
ORIVA24041961
Status last verified
Feb 2026
First submitted
10 Feb 2026
Last updated
19 Feb 2026
Results posted
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

A Phase 2 study testing Low erythrodiol dose, Medium erythrodiol dose and High erythrodiol dose in people with Atherosclerosis Cardiovascular Disease, run by Spanish National Research Council at 1 site in Spain.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 7 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: opening soon, as of the sponsor's last update on 19 Feb 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Spain. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Javier Perona S. Perona, PhD (34954611550, perona@ig.csic.es), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Plasma erythrodiol concentration (time frame: 4 months since the last intervention session). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 19 Feb 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in